Generic FloLipid Availability
Last updated on Apr 10, 2025.
FloLipid is a brand name of simvastatin, approved by the FDA in the following formulation(s):
FLOLIPID (simvastatin - suspension;oral)
-
Manufacturer: SALERNO PHARMS
Approval date: April 21, 2016
Strength(s): 20MG/5ML [RLD], 40MG/5ML [RLD]
Is there a generic version of FloLipid available?
No. There is currently no therapeutically equivalent version of FloLipid available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of FloLipid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Liquid oral simvastatin compositions
Patent 10,300,041
Issued: May 28, 2019
Inventor(s): Driver Phillip
Assignee(s): Rosemont Pharmaceuticals LTDAqueous suspensions for oral administration are disclosed that include simvastatin having a dof simvastatin particles of less than about 100 μm as the active agent. The aqueous suspension also includes simvastatin as about 20 mg to about 80 mg per 5 ml of the aqueous suspension, a suspending agent as about 20 mg to about 50 mg of the aqueous suspension, a wetting agent, an antimicrobial preservative, an antifoaming agent, water, and a buffering system providing the aqueous suspension with a pH of about 6.4 to about 7. Methods of making such a suspension and methods of treatments in orally administering the same are also disclosed.
Patent expiration dates:
- April 26, 2027✓
- April 26, 2027
-
Liquid oral simvastatin compositions
Patent 9,597,289
Issued: March 21, 2017
Inventor(s): Driver Phillip
Assignee(s): ROSEMONT PHARMACEUTICALS LTD.A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 μm in diameter. The present invention also includes uses of the suspension and methods of making the suspension.
Patent expiration dates:
- February 23, 2030✓
- February 23, 2030
More about FloLipid (simvastatin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Latest FDA alerts (9)
- Side effects
- Dosage information
- During pregnancy
- Drug class: statins
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.